RAHWAY, N.J., May 12, 2026
Merck announced a major expansion of its oncology research portfolio ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting new long-term clinical data across more than 25 cancer types. The company will present findings from over 100 abstracts during ASCO 2026, scheduled from May 29 to June 2 in Chicago, reinforcing the growing impact of KEYTRUDA, personalized cancer vaccines, and next-generation antibody-drug conjugates in oncology treatment strategies.
Five-Year Melanoma Data Strengthens Personalized Cancer Vaccine Program
One of the most closely watched presentations will feature five-year follow-up data from the Phase 2b KEYNOTE-942 trial evaluating intismeran autogene (mRNA-4157/V940) in combination with KEYTRUDA (pembrolizumab) for patients with resected high-risk melanoma. The investigational therapy combines an individualized neoantigen vaccine approach with immune checkpoint inhibition, representing a significant advancement in personalized cancer immunotherapy. Merck stated the long-term findings continue to demonstrate the potential durability of the treatment combination, an important factor for reducing recurrence risk in melanoma patients after surgery. The data further strengthen Merck’s position in the rapidly evolving field of mRNA-based oncology therapeutics, an area receiving increasing investment and clinical interest globally.
KEYTRUDA Expands Leadership in Breast and Lung Cancer Research
Merck will also present final analysis results from the Phase 3 KEYNOTE-522 trial, which evaluated KEYTRUDA plus chemotherapy in patients with high-risk early-stage triple-negative breast cancer (TNBC). According to the company, the updated results continue to show meaningful survival benefits, reinforcing the therapy’s importance in earlier-stage breast cancer treatment. TNBC remains one of the most aggressive forms of breast cancer, with limited targeted treatment options, making long-term survival improvements clinically significant.
Advertisement
Additional attention will focus on Merck’s antibody-drug conjugate pipeline, particularly sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate being studied for advanced non-small cell lung cancer. Data from the Phase 3 OptiTROP-Lung05 study conducted in China will be presented at ASCO 2026. The company also confirmed that data from the Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating KEYTRUDA plus Trodelvy in metastatic TNBC will be included in the official ASCO 2026 Press Program, highlighting the growing importance of combination immunotherapy and targeted drug conjugates in oncology care.
Merck Expands Oncology Pipeline Beyond Checkpoint Inhibitors
The ASCO presentations reflect Merck’s broader strategy to diversify beyond checkpoint inhibitors while maintaining leadership in cancer immunotherapy. The company’s oncology pipeline now includes individualized neoantigen therapies, antibody-drug conjugates, T-cell engagers, bispecific antibodies, and next-generation immunotherapies across multiple tumor types. Merck’s pipeline currently includes more than 50 Phase 2 programs and over 30 Phase 3 programs, underlining the scale of its ongoing oncology development efforts.
Company executives stated that the upcoming ASCO presentations demonstrate the “strong momentum” of Merck’s oncology research platform and its commitment to addressing unmet medical needs in cancer treatment. With increasing competition emerging in immuno-oncology, the company is accelerating development of differentiated therapies capable of delivering improved long-term survival outcomes and personalized treatment approaches for patients worldwide.
Source: Merck press release
